Polsinelli expands Hatch-Waxman and litigation practices
Firm adds new chair of Hatch-Waxman & Biologics Practice is an FDA and pharma litigation expert who will ‘provide clarity in an uncertain post-Chevron world’ | Shareholder brings extensive trial and appellate experience in automotive industry.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
31 July 2026 The ex-Greenberg Traurig shareholder will oversee the office’s 14,000-strong patent division, as the agency prepares for the departure of deputy director Coke Morgan Stewart.
29 July 2026 The engineer-turned-lawyer joins as a principal, bringing 15 years of experience advising on patent strategy across AI, software, and medical devices.
27 July 2026 The firm has added partners with expertise in life sciences, technology disputes and trademark strategy, alongside leadership changes at its Hong Kong affiliate.